About US
Contact us
-
Merck launches Sivextro in U.K.Merck ($MRK) is launching Sivextro, the newly approved antibiotic it picked up in its $9.5 billion buyout ofCubist, in the U.K.Pharmafilereports it is the first oral treatment to be released in the ox2015/6/8
-
Fresh off Novartis consumer deal, GSK slices off 350 workers to hit cost-squeezing targetsNow that it's teamed up with Novartis' ($NVS) consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's ($GSK) OTC business is bigger than ever. But its payroll is about to get2015/6/5
-
Sanofi bags 'breakthrough' tag for new Genzyme rare disease medSanofi's ($SNY) rare disease-focused unitGenzymepicked up theFDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease. The French drugmaker is set for2015/6/5
-
Jury sides with Merck and its execs in gender-bias caseMerck & Co. ($MRK) won the day in a gender discrimination suit on Tuesday, as a federal jury found that former employee Kerri Colicchio failed to prove she was discriminated against because of h2015/6/4
-
Merck's 'landmark' Zetia data hits NEJM, giving a boost to all LDL-fighting medsThe nitty-gritty on Merck & Co.'s ($MRK)Zetiaoutcomes trial is now revealed--and it's not just good news for the cholesterol-fighting drug and its combo-pill sister Vytorin. It's good for all high2015/6/4
-
Roche, Novartis and Bayer snag NICE OKsThe U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche ($RHHBY),2015/6/3
-
Tumor tests for immuno-oncology drugs need some work, cancer experts sayDrugmakers are quick to cite results from tests for new immuno-oncology meds, with companies such as Bristol-Myers Squibb ($BMY), Merck ($MRK), Roche ($RHHBY) and Pfizer ($PFE) screening for biomarker2015/6/3
-
Top oncologist joins chorus of pricing critics in high-profile ASCO speechPharma types are getting a wee bit defensive about critics' attacks on cancer drug prices, if response toFiercePharma's recent coverage is any indication. But the criticism just keeps on coming, even2015/6/2
-
Look for orphan drugs to keep fueling M&A, Moody's saysOrphan drugsare attractive to make thanks to premium pricing prospects, limited competition and regulatory perks. But those factors also make them attractive to buy, and they'll continue to spur M&2015/6/2
-
New standout Imbruvica data bode well for market expansion in CLLCHICAGO--Johnson & Johnson ($JNJ) and AbbVie's ($ABBV)Imbruvicahas already shown in one Phase III study that it can extend progression-free survival in patients with previously treated chronic lym2015/6/1